Free Trial
NASDAQ:SNTI

Senti Biosciences Q4 2024 Earnings Report

Senti Biosciences logo
$5.00 +0.13 (+2.67%)
Closing price 04/25/2025 04:00 PM Eastern
Extended Trading
$4.89 -0.11 (-2.10%)
As of 04/25/2025 07:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Senti Biosciences EPS Results

Actual EPS
-$0.67
Consensus EPS
-$3.13
Beat/Miss
Beat by +$2.46
One Year Ago EPS
N/A

Senti Biosciences Revenue Results

Actual Revenue
$5.86 million
Expected Revenue
$2.80 million
Beat/Miss
Beat by +$3.06 million
YoY Revenue Growth
N/A

Senti Biosciences Announcement Details

Quarter
Q4 2024
Time
Before Market Opens
Conference Call Date
Thursday, March 20, 2025
Conference Call Time
4:00PM ET

Upcoming Earnings

Senti Biosciences' Q1 2025 earnings is scheduled for Thursday, May 8, 2025, with a conference call scheduled on Friday, May 9, 2025 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Senti Biosciences Earnings Headlines

Crypto’s crashing…but we’re still profiting
Most traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess. The news is screaming fear. But while most traders watch their portfolios tank…
Senti Bio appoints James Trager to Scientific Advisory Board
See More Senti Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Senti Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Senti Biosciences and other key companies, straight to your email.

About Senti Biosciences

Senti Biosciences (NASDAQ:SNTI) operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma. It also develops SENTI-401, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer/CRC cells. In addition, the company develops Tumor-Associated Antigen and Protective Antigen Paired Discovery Platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells. The company has a strategic collaboration with Celest Therapeutics (Shanghai) Co. Ltd for the clinical development of SENTI-301A to treat solid tumors. Senti Biosciences, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

View Senti Biosciences Profile

More Earnings Resources from MarketBeat